Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Breast cancer research : BCR - 1 Mar 2011

Sanchez Cesar G, Ma Cynthia X, Crowder Robert J, Guintoli Therese, Phommaly Chanpheng, Gao Feng, Lin Li, Ellis Matthew J

Abstract excerpt

INTRODUCTION: Inhibition of phosphatidylinositol-3-kinase (PI3K) induces apoptosis when combined with estrogen deprivation in estrogen receptor (ER)-positive breast cancer. The aims of the present study were to identify effective PI3K pathway inhibitor and endocrine therapy combinations, to evaluate the effect of PI3K pathway mutations and estrogen dependency on tumor response, and to determine the relevance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Everolimus

Share to Fulvestrant

Share to Morpholines

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 21362200
DOI: 10.1186/bcr2833
PMCID: PMC3219179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.PMID 21362200Read ↗

Nexus Between PI3K/AKT and Estrogen Receptor Signaling in Breast CancerSemantic proximity Read ↗

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.Semantic proximity Read ↗

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoSemantic proximity Read ↗

<i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Semantic proximity Read ↗

Overview of the relevance of PI3K pathway in HR-positive breast cancerSemantic proximity Read ↗

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Semantic proximity Read ↗

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.Semantic proximity Read ↗

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.Semantic proximity Read ↗

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.